Shanghai Haohai Biological Technology Co., Ltd. Class H (HK:6826)
:6826
Top Page
Shanghai Haohai Biological Technology Co., Ltd. Class H
(6826)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$24.50
▼(-1.61% Downside)
Action:ReiteratedDate:03/30/26
The score is driven primarily by solid financial stability (low leverage, positive earnings and cash flow) but is held back by weakening fundamentals (TTM revenue decline and margin compression). Technical signals are notably bearish (below key moving averages with negative MACD and low RSI), while valuation is supported by a strong dividend yield with a moderate P/E.
Positive Factors
Strong balance sheet / low leverage
Low leverage and a conservative capital structure provide durable financial flexibility: the company can fund R&D, absorb demand shocks, pursue selective M&A or capex without relying heavily on external debt, and sustain operations through multi-quarter revenue softness.
Negative Factors
Recent revenue decline
A sustained decline in top-line growth erodes scale benefits and reduces levers for margin recovery. If procedure volumes or market share do not rebound, the company may face greater pressure on pricing, R&D returns and its ability to fund growth organically over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / low leverage
Low leverage and a conservative capital structure provide durable financial flexibility: the company can fund R&D, absorb demand shocks, pursue selective M&A or capex without relying heavily on external debt, and sustain operations through multi-quarter revenue softness.
Read all positive factors
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$9.37B
Dividend Yield4.28%
Average Volume (3M)211.55K
Price to Earnings (P/E)20.8
Beta (1Y)0.81
Revenue Growth-8.49%
EPS Growth-9.46%
CountryHK
Employees2,156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding35,929,040
10 Day Avg. Volume238,704
30 Day Avg. Volume211,551
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.94
Price to Sales (P/S)2.13
P/FCF Ratio11.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.28
Revenue Forecast (FY)HK$3.01B
Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Haohai Biological Technology Co., Ltd. is a leading biotechnology company based in Shanghai, China, specializing in the research, development, production, and commercialization of innovative medical devices and biopharmaceuticals. The com...
How the Company Makes Money
The company makes money mainly by selling its medical device and biomedical material products through hospital/clinic and distributor channels, with revenue recognized from product sales to customers. Key revenue streams typically include: (1) Oph...
Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
84
Very Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.40B | 2.68B | 2.63B | 2.10B | 1.75B |
| Gross Profit | 1.56B | 1.87B | 1.85B | 1.45B | 1.26B |
| EBITDA | 480.36M | 549.05M | 713.41M | 447.55M | 550.45M |
| Net Income | 244.51M | 420.45M | 416.12M | 180.47M | 352.23M |
Balance Sheet | |||||
| Total Assets | 6.72B | 7.12B | 7.11B | 6.89B | 6.95B |
| Cash, Cash Equivalents and Short-Term Investments | 2.52B | 2.76B | 2.75B | 2.56B | 2.91B |
| Total Debt | 398.67M | 448.43M | 407.95M | 118.26M | 105.51M |
| Total Liabilities | 1.12B | 1.20B | 1.09B | 990.02M | 890.07M |
| Stockholders Equity | 5.42B | 5.58B | 5.65B | 5.51B | 5.71B |
Cash Flow | |||||
| Free Cash Flow | 446.40M | 283.08M | 367.22M | -85.85M | 70.19M |
| Operating Cash Flow | 628.50M | 648.57M | 634.45M | 231.30M | 342.29M |
| Investing Cash Flow | -10.81M | 282.28M | -376.65M | -681.82M | -148.09M |
| Financing Cash Flow | -509.70M | -390.35M | -257.73M | -288.35M | -231.25M |
Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis
Negative
24.90
Price Trends
24.84
Negative
25.69
Negative
26.39
Negative
Market Momentum
-0.73
Positive
34.76
Neutral
12.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6826, the sentiment is Negative. The current price of 24.9 is above the 20-day moving average (MA) of 23.38, above the 50-day MA of 24.84, and below the 200-day MA of 26.39, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 34.76 is Neutral, neither overbought nor oversold. The STOCH value of 12.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6826.
Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$25.94B | 42.36 | 15.32% | ― | 48.38% | ― | |
64 Neutral | HK$9.37B | 20.83 | 4.47% | 4.28% | -8.49% | -9.46% | |
54 Neutral | HK$18.02B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$10.63B | -77.24 | -11.84% | ― | 1219.19% | 25.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$20.03B | -25.84 | -17.26% | ― | 964.40% | 65.90% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
22.24
0.75
3.49%
HK:1672
Ascletis Pharma, Inc.
16.98
12.03
243.03%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.89
88.65%
HK:2162
Keymed Biosciences, Inc.
71.35
32.70
84.61%
HK:2171
CARsgen Therapeutics Holdings Ltd.
18.39
7.51
69.03%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
63.50
51.10
412.10%
Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Haohai Cuts Capital After Cancelling Over 3.2 Million H Shares
Mar 20, 2026
Shanghai Haohai Biological Technology Co., Ltd. has adjusted its share capital structure following earlier issuances of A and H shares, and now reports a total of 229,980,895 shares, consisting of 194,051,855 A shares and 35,929,040 H shares. The ...
Shanghai Haohai Settles Profit Guarantee Adjustments in Ophthalmology Unit Acquisition
Mar 20, 2026
Shanghai Haohai Biological Technology announced the finalisation of profit guarantee arrangements tied to its staged acquisition of Shenzhen New Industries Material of Ophthalmology Co., Ltd., in which its wholly owned subsidiary agreed to buy equ...
Shanghai Haohai Profit Slumps in 2025 as Revenue Falls but Dividend Held Steady
Mar 20, 2026
Shanghai Haohai Biological Technology reported 2025 revenue of RMB2.45 billion, down 8.71% year on year, with net profit attributable to shareholders dropping 40.30% to RMB251.01 million and adjusted net profit down 57.67%. The company reduced RD ...
Shanghai Haohai Biological Proposes Final Dividend for 2025
Mar 20, 2026
Shanghai Haohai Biological Technology Co., Ltd. has proposed a final ordinary cash dividend of RMB 0.6 per share for the financial year ended 31 December 2025, subject to shareholders’ approval. The dividend will be paid in Hong Kong dollars...
Haohai Biological Sets March 2026 Board Meeting to Review 2025 Results and Dividend Plan
Mar 10, 2026
Shanghai Haohai Biological Technology Co., Ltd. has scheduled a board meeting for 20 March 2026 to review and approve the consolidated annual results for the year ended 31 December 2025. The board will also consider recommending a final dividend, ...
Shanghai Haohai Issues Preliminary 2025 Results Showing Profit Slide
Feb 27, 2026
Shanghai Haohai Biological Technology Co., Ltd. has reported preliminary unaudited figures for 2025 prepared under China Accounting Standards, indicating a decline in both revenue and profitability. The company cautioned investors that these numbe...
Haohai Biological Defends Valuation and Clarifies Ownership in Jiangxi Ruiji Equity Deal
Jan 7, 2026
Shanghai Haohai Biological Technology Co., Ltd. has issued a supplemental announcement regarding its connected transaction to acquire equity in Jiangxi Ruiji Bio-Engineering Technology Co., Ltd., elaborating on the valuation basis and ownership st...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.